Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients?
Tacrolimus (FK506) is the most widely used anti-rejection drug in kidney transplantation, especially its extended release Tacrolimus formulation (ER-Tac, Advagraf), which is used when target blood levels can be difficult to reach in high metabolizer patients. In this retrospective monocentric study...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Codon Publications
2020-05-01
|
Series: | Journal of Renal and Hepatic Disorders |
Subjects: | |
Online Access: | https://jrenhep.com/index.php/jrenhep/article/view/68 |
id |
doaj-18d1b3d8bf004327a923319f540a5489 |
---|---|
record_format |
Article |
spelling |
doaj-18d1b3d8bf004327a923319f540a54892020-11-25T03:34:56ZengCodon PublicationsJournal of Renal and Hepatic Disorders2207-37442020-05-014110.15586/jrenhep.2020.68Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients?Paolo Carta0Federica Curci1Leonardo Caroti2Larti Aida3Lorenzo Di Maria4Lino Cirami5Nephrology and Dialysis Unit, Careggi University Hospital, Florence, Italy.Nephrology and Dialysis Unit, Careggi University Hospital, Florence, Italy.Nephrology and Dialysis Unit, Careggi University Hospital, Florence, Italy.Nephrology and Dialysis Unit, Careggi University Hospital, Florence, Italy.Nephrology and Dialysis Unit, Careggi University Hospital, Florence, Italy.Nephrology and Dialysis Unit, Careggi University Hospital, Florence, Italy. Tacrolimus (FK506) is the most widely used anti-rejection drug in kidney transplantation, especially its extended release Tacrolimus formulation (ER-Tac, Advagraf), which is used when target blood levels can be difficult to reach in high metabolizer patients. In this retrospective monocentric study, we analyzed the effect of a switch from ER-Tac to LifeCycle Pharma Tacrolimus (LPCT, Envarsus) on the dose/level ratio of FK506 in high metabolizer patients that cannot achieve target blood levels in the first 6 months after transplantation. We observed a statistically significant improvement in the level to dose ratio after the switch. Renal function remained stable. We also observed a reduction in the development of tremors. Our data suggest that LPCT can be used in a safer way in high metabolizer kidney transplant recipients. https://jrenhep.com/index.php/jrenhep/article/view/68kidney transplantation; extended-dose-release Tacrolimus; melt-dose Tacrolimus; renal function; tremors; high metabolizer recipients |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Paolo Carta Federica Curci Leonardo Caroti Larti Aida Lorenzo Di Maria Lino Cirami |
spellingShingle |
Paolo Carta Federica Curci Leonardo Caroti Larti Aida Lorenzo Di Maria Lino Cirami Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients? Journal of Renal and Hepatic Disorders kidney transplantation; extended-dose-release Tacrolimus; melt-dose Tacrolimus; renal function; tremors; high metabolizer recipients |
author_facet |
Paolo Carta Federica Curci Leonardo Caroti Larti Aida Lorenzo Di Maria Lino Cirami |
author_sort |
Paolo Carta |
title |
Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients? |
title_short |
Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients? |
title_full |
Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients? |
title_fullStr |
Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients? |
title_full_unstemmed |
Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients? |
title_sort |
conversion from extended-dose-release tacrolimus to melt-dose tacrolimus in high metabolizer patients: is the new formulation of lpct the best option for high metabolizer kidney transplanted patients? |
publisher |
Codon Publications |
series |
Journal of Renal and Hepatic Disorders |
issn |
2207-3744 |
publishDate |
2020-05-01 |
description |
Tacrolimus (FK506) is the most widely used anti-rejection drug in kidney transplantation, especially its extended release Tacrolimus formulation (ER-Tac, Advagraf), which is used when target blood levels can be difficult to reach in high metabolizer patients. In this retrospective monocentric study, we analyzed the effect of a switch from ER-Tac to LifeCycle Pharma Tacrolimus (LPCT, Envarsus) on the dose/level ratio of FK506 in high metabolizer patients that cannot achieve target blood levels in the first 6 months after transplantation.
We observed a statistically significant improvement in the level to dose ratio after the switch. Renal function remained stable. We also observed a reduction in the development of tremors.
Our data suggest that LPCT can be used in a safer way in high metabolizer kidney transplant recipients.
|
topic |
kidney transplantation; extended-dose-release Tacrolimus; melt-dose Tacrolimus; renal function; tremors; high metabolizer recipients |
url |
https://jrenhep.com/index.php/jrenhep/article/view/68 |
work_keys_str_mv |
AT paolocarta conversionfromextendeddosereleasetacrolimustomeltdosetacrolimusinhighmetabolizerpatientsisthenewformulationoflpctthebestoptionforhighmetabolizerkidneytransplantedpatients AT federicacurci conversionfromextendeddosereleasetacrolimustomeltdosetacrolimusinhighmetabolizerpatientsisthenewformulationoflpctthebestoptionforhighmetabolizerkidneytransplantedpatients AT leonardocaroti conversionfromextendeddosereleasetacrolimustomeltdosetacrolimusinhighmetabolizerpatientsisthenewformulationoflpctthebestoptionforhighmetabolizerkidneytransplantedpatients AT lartiaida conversionfromextendeddosereleasetacrolimustomeltdosetacrolimusinhighmetabolizerpatientsisthenewformulationoflpctthebestoptionforhighmetabolizerkidneytransplantedpatients AT lorenzodimaria conversionfromextendeddosereleasetacrolimustomeltdosetacrolimusinhighmetabolizerpatientsisthenewformulationoflpctthebestoptionforhighmetabolizerkidneytransplantedpatients AT linocirami conversionfromextendeddosereleasetacrolimustomeltdosetacrolimusinhighmetabolizerpatientsisthenewformulationoflpctthebestoptionforhighmetabolizerkidneytransplantedpatients |
_version_ |
1724556567319150592 |